Belgium

All.Can around the world

All.Can Belgium

Cancer care in Belgium

The quality of cancer care in Belgium, as measured by five-year survival for treatable cancers such as breast cancer, cervical cancer and colorectal cancer, is better than the EU average.1 However, cancer remains one of the most common causes of death. Incidence and prevalence of cancer have been rising along with an ageing population and more effective treatment solutions.2 The most frequently reported cancers for males are, respectively, prostate cancer, lung cancer and colon cancer. For females the most frequent cancer is breast cancer, with more than one third of reported cases, followed first by colon cancer and lung cancer.3 The challenge to improve cancer care and ensure sustainable cancer care remains high on the agenda and calls for action.

All.Can Belgium initiative

All.Can Belgium is a multi-stakeholder platform working to mobilise the Belgian cancer care community in order to achieve specific, implementable and ambitious projects. The aim is to achieve sustainable, efficient, innovative and patient-centred cancer care. All.Can Belgium brings together patient and care representatives, healthcare professionals, health experts, health economists, policymakers and industry representatives who are committed to this objective.

All.Can Belgium has five main goals:

  • Align stakeholders on a joint vision on cancer care and create stakeholder support for this vision
  • Initiate and realise projects to deliver on the vision
  • Propose solutions that contribute to more efficient and innovative cancer care
  • Proactively provide input to the policy debate
  • Create societal support for the vision.

The scope of the All.Can Belgium initiative includes the following dimensions:

  • The value and adoption of innovative, improved approaches in cancer care
  • Resource allocation
  • Patient access
  • Quality of care.

Key milestones and activities

  • Policy report. The policy report for Belgium will reflect on the Belgian context in relation to the policy recommendations presented in the All.Can international policy report. It will summarise key facts and figures about cancer care in Belgium. Furthermore, the policy analysis will help to define priority working areas for All.Can Belgium.
  • Participation in the global All.Can patient survey. This survey will allow a better understanding of patient experiences in relation to the information, support and care received during their treatment. It provides an opportunity to benchmark the perspective of Belgian patients to that of patients in other participating countries.

 

References:

1. OECD/European Observatory on Health Systems and Policies. 2017. Belgium: Country Health Profile 2017, State of Health in the EU. Available from: https://www.oecd-ilibrary.org/social-issues-migration-health/belgium-country-health-profile-2017_9789264283299-en [accessed 15 June 2018]

2. Cancon. 2017. European Guide on Quality Improvement in Comprehensive Cancer Control. Available from: https://www.iccp-portal.org/sites/default/files/resources/Cancon_PolicyPaper2_032017.pdf [accessed 18 June 2018]

3. Stichting Tegen Kanker. Kanker in cijfers. Available from: https://www.kanker.be/alles-over-kanker/kanker-cijfers [accessed 18 June 2018]

Disclaimer:

The All.Can initiative is made up of leading representatives of patient organisations, policy makers, health care professionals, science and industry. All the publications produced under the initiative reflect the consensus of All.Can members who have full editorial control. The All.Can initiative in Belgium is financially supported by Bristol-Myers Squibb and MSD. None of the content developed in discussions and activities of the All.Can initiative contains direct or indirect references to specific medicinal products or therapies. Use of content from this website is permitted provided that the source of information is clearly mentioned.

All.Can is a trademark of The Health Policy Partnership Ltd.

Steering group

Dr Pia Cox

Dr Pia Cox

Co-founder and Board Member, Pink Ribbon

Dr Marc Vanden Bulcke

Dr Marc Vanden Bulcke

Senior Principal Scientist Sciensano (Kankercentrum)

Professor Dr Dominique Vandijck

Professor Dr Dominique Vandijck

Director Q&S, Zorgnet-Icuro; Professor of Patient Safety, Health Economics and Healthcare Innovation, UHasselt

Dr Didier Vander Steichel

Dr Didier Vander Steichel

General Director, Stichting tegen Kanker/ Fondation contre le cancer

Ine Somers

Ine Somers

Member of Federal Parliament, Commission of Public Health

Gilles Poncé

Gilles Poncé

Head of Governmental Affairs, Pricing and Reimbursement – Market Access Director, Bristol-Myers Squibb

Brecht Vanneste

Brecht Vanneste

Executive Director, External Affairs, MSD Belgium & Luxembourg

Dr Ri De Ridder

Dr Ri De Ridder

Health Expert (former Director General, RIZIV-INAMI)

Professor Ahmad Awada

Professor Ahmad Awada

Head of the Medicine Department and the Medical Oncology Clinic, Jules Bordet Institute